share_log

CRISPR Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers

CRISPR Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers

CRISPR Therapeutics | S-3ASR：“知名成熟发行人”证券注册声明
美股sec公告 ·  08/05 17:27
Moomoo AI 已提取核心信息
CRISPR Therapeutics AG, a leading gene editing company, has announced the availability of up to $378,641,978 of its common shares for sale through an Open Market Sale AgreementSM with Jefferies LLC. The shares will be offered at market prices and sold on The Nasdaq Global Market under the ticker symbol 'CRSP'. The proceeds from the sale are intended to fund research and clinical development of pipeline candidates, platform extensions, manufacturing infrastructure, working capital, and general corporate purposes. The company has previously issued 1,642,636 common shares under the Sales Agreement and plans to use the additional funds to continue advancing its CRISPR/Cas9-based therapeutics, including the landmark CRISPR-based therapy, CASGEVY, which was approved in 2023.
CRISPR Therapeutics AG, a leading gene editing company, has announced the availability of up to $378,641,978 of its common shares for sale through an Open Market Sale AgreementSM with Jefferies LLC. The shares will be offered at market prices and sold on The Nasdaq Global Market under the ticker symbol 'CRSP'. The proceeds from the sale are intended to fund research and clinical development of pipeline candidates, platform extensions, manufacturing infrastructure, working capital, and general corporate purposes. The company has previously issued 1,642,636 common shares under the Sales Agreement and plans to use the additional funds to continue advancing its CRISPR/Cas9-based therapeutics, including the landmark CRISPR-based therapy, CASGEVY, which was approved in 2023.
CRISPR Therapeutics AG，一家领先的基因编辑公司，已宣布通过与Jefferies LLC的开放市场销售协议Sm，提供高达$378641978的普通股出售。这些股票将以市场价格在纳斯达克全球市场上的逐笔明细标的为“CRSP”的股票进行出售。所筹集到的款项将用于资助管道候选、平台扩展、基础设施制造行业、营运资本和一般公司用途的研究和临床开发。该公司已在销售协议下发行了1，642，636股普通股，并计划使用额外资金继续推进其CRISPR / Cas9基因编辑疗法，包括里程碑式的CRISPR基因编辑疗法CASGEVY，该疗法已在2023年获批。
CRISPR Therapeutics AG，一家领先的基因编辑公司，已宣布通过与Jefferies LLC的开放市场销售协议Sm，提供高达$378641978的普通股出售。这些股票将以市场价格在纳斯达克全球市场上的逐笔明细标的为“CRSP”的股票进行出售。所筹集到的款项将用于资助管道候选、平台扩展、基础设施制造行业、营运资本和一般公司用途的研究和临床开发。该公司已在销售协议下发行了1，642，636股普通股，并计划使用额外资金继续推进其CRISPR / Cas9基因编辑疗法，包括里程碑式的CRISPR基因编辑疗法CASGEVY，该疗法已在2023年获批。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息